Researchers at Texas A&M University College of Medicine have developed a new therapy that may slow the progression of ...

Zeteo Biomedical LLC today announced the launch of its ZTech-P CygnusMR™ and CygnusSDX™ delivery devices, designed for ...

Cognitive neuroscientist Eleanor Maguire, PhD, whose studies of London taxi drivers' brains helped transform memory research, ...

A Massachusetts man is the only one in the country who has tried a nasal spray treatment for Alzheimer's. He's going to help ...

Almost 100,000 bottles of nasal spray were recalled for a "microbial failure" that led to multiple complaints from customers.

As a community pharmacist in Nova Scotia, I have witnessed the ongoing effects of the opioid crisis firsthand. This public ...

STATEN ISLAND, N.Y. — The U.S. Food and Drug Administration (FDA) has announced a recall of 89,312 bottles of a popular nasal ...

Retired electrician Joe Walsh in December became the first Alzheimer’s patient to try a nasal spray used to treat other ...

The drug is designed to reduce inflammation in the brain and has been used on MS, cancer and migraine headaches.

The Food and Drug Administration (FDA) has expanded its approval of a ketamine-derived nasal spray, Spravato (esketamine), as a standalone therapy for adults with treatment-resistant depression.

The following is a summary of “Anatomical and physiological contributions of nasal turbinate vessels and lymphatics to the pathogenesis of nasal congestion in recurrent headaches: A pilot study,” ...

The FDA’s latest approval of the nasal spray Spravato (esketamine) CIII marks a major shift in how major depressive disorder is managed, allowing people who have tried at least two oral ...